Contrasted perceptions of Alzheimer's disease in the media and in the cultural productions: changes from 2010 to 2018

Ngatcha-Ribert, Laëtitia

doi:10.1684/pnv.2019.0829

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Objects. Inclusion criteria were as follows: ① the patients met the diagnostic criteria for AD in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) [9]; ② the patients had to be sent to the psychiatric ward and required hospitalization due to aggressive, psychiatric, or agitated signs and symptoms so severe that could damage self-cognitive function, and treatment with antipsychotics was considered reasonable by the clinician; ③ 7 d before registration, the patients' psychiatric or slightly agitated symptoms happened daily; ④ the patients were hospitalized during the study; ⑤ the patients had complete clinical data; and ⑥ the study met the World Medical Association Declaration of Helsinki [10].…”

Section: Enrollment Of Studymentioning

confidence: 99%

Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer’s Disease

Fang

Zhang

Zhao

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. To explore the effect of resveratrol (RES) combined with donepezil hydrochloride on inflammatory factor level and cognitive function level of patients with Alzheimer’s disease (AD). Methods. A total of 90 AD patients treated in our hospital from June 2019 to June 2020 were selected as the study objects and divided into the control group (CG) and experimental group (EG) by the randomized and double-blind method, with 45 cases each. Patients in CG received donepezil hydrochloride treatment, and on this basis, those in EG received additional RES treatment, so as to compare the clinical indicators between the two groups. Results. Compared with CG after treatment, EG obtained significantly higher good rate, MMSE score, and FIM score ( P < 0.05 ) and obviously lower clinical indicators and ADAS-cog score ( P < 0.001 ), and between CG and EG, no obvious difference in total incidence rate of adverse reactions was observed after treatment ( P > 0.05 ). Conclusion. Combining RES with donepezil hydrochloride has significant clinical efficacy in treating AD, which can effectively improve patients’ inflammatory factor indicators, promote their cognitive function, and facilitate patient prognosis.

show abstract

Section: Enrollment Of Studymentioning

confidence: 99%